In the 2012 edition of its Top 10 Fashion and Beauty Startups, Forbes.com ranked only one company, online retailer Mode-sty, above Personal Cell Sciences.  Personal Cell Sciences, a privately-held corporation, has brought to market “U Autologous,” a cutting-edge anti-aging skincare whose ingredients include a user’s own stem cells.  The crux of the recipe is pretty simple to grasp and easily understandable as to why it’s effective.  Adipose, or fat, stem cells are removed from a customer through liposuction, sent off for processing and transformed into a skin product containing the youthful cells to keep skin supple and wrinkle-free.  The remaining cells are stored for subsequent orders or for other additional future uses, which given new innovations in stem cell therapies, could ultimately be a wide array of applications.

But the company is private, you may say.  That is indeed true, but Personal Cell Sciences is owned by John Arnone, the Chief Executive Officer at American CryoStem Corp. (OTCQB: CRYO), a fact that ties these two companies together in more ways than just the having the same top exec.

Eatontown, New Jersey-based American CryoStem is an upstart biotech company focused on marketing its clinical processing services and patented products for adipose tissue and Adipose Derived Adult Stem Cells (ADSCs).  The company is the contract manufactures for U Autologous as well as the storage facility for the stem cells.  American CryoStem utilizes its patented animal-free media to culture an individual’s stem cells to create the key ingredient in U Autologous, Autokine-CMTM, which contains the individual’s proteins, growth factors and cytokines collected from their ADSCs.  Located near New York City, the fashion and money hub of the world with a lengthy list of plastic surgeons selling the product to patients, the new clinically-proven product is quickly emerging as a blockbuster.  While the skin product got the immediate notoriety, the stem cells can also be used for augmentations – such as breast or buttock – and carries the possibility to replace riskier materials that are used every day in those procedures.

While these products drive revenue for American CryoStem already, the patented media should also be a focus of investors for what it could bring to the company and its stakeholders.  Cultures are used in virtually every aspect of medicine from early development of compounds and regenerative medicines to tests in medical clinics.  The most-commonly used medium, or albumin, today for storing cell cultures or for in vitro diagnostics is fetal bovine serum.  Yes, it comes from cows (fetuses, actually, as the name implies).  American CryoStem’s product is human-derived (eliminating ethical and biological arguments out there today about the use of bovine-derived material) and could prove a superior product in general.

The company has been issued one patent, with four more pending, covering a broad base of 12 different types of mediums to protect its intellectual property and establish it as the clear leader in the space.

Approximately three-quarters of a million liters of fetal bovine serum are sold each year, making it a better than $500 million industry.  European regulators are starting to make the transition to albumins that cannot have touched an animal in the manufacturing chain.  American CryoStem’s issued patent for human albumin covers the European Union.  To that end, it is discernible that other countries will soon follow, positioning American CryoStem as the potential industry stalwart and in a unique spot for serious growth in the sector.  That is in addition to its cryopreservation services, U Autologous revenue stream, wound care product and various other potential applications related to regenerative medicines.  Proper due diligence of this up-and-comer is, as always, encouraged.

American CryoStem (CRYO) Stock Quote and News:

---

Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.